How to cite item

Bevacizumab with first-line chemotherapy for Medicare patients with metastatic colorectal cancer: Do the risks outweigh the benefits?

   
@article{TGC707,
	author = {John H. Strickler},
	title = {Bevacizumab with first-line chemotherapy for Medicare patients with metastatic colorectal cancer: Do the risks outweigh the benefits?},
	journal = {Translational Gastrointestinal Cancer},
	volume = {2},
	number = {1},
	year = {2012},
	keywords = {},
	abstract = {No single randomized controlled trial (RCT) can address
every possible clinical scenario in the practice of oncology.
Registry studies are a valuable tool to further describe the
effectiveness of an intervention when discrepancies exist
between a clinical trial population and the “real world”
patient population, or when additional trials are not feasible.
In a recent publication, Meyerhardt et al. (1) analyzed the
Surveillance, Epidemiology, and End Results (SEER)-
Medicare database to determine the overall survival (OS)
benefit of adding bevacizumab to combination chemotherapy
for Medicare patients with metastatic colorectal cancer
(CRC).},
	url = {https://tgc.amegroups.com/article/view/707}
}